. CoQ 10 deficiencies may also result from pathogenic mutations in genes not directly related to CoQ 10 biosynthesis, and such cases are referred to as secondary CoQ 10 deficiencies [Turunen et al., 2004; Montero et al., 2005 Montero et al., , 2009 Quinzii et al., 2005; Aeby et al., 2007; Gempel et al., 2007; Le Ber et al., 2007; Miles et al., 2008; Sacconi et al., 2010; Cótan et al., 2011; Quinzii and Hirano, 2011] .
The definitive diagnosis of CoQ 10 deficiency, in most patients, is based on measurements of CoQ 10 levels in muscle. Additionally, patients with primary CoQ 10 deficiency frequently show decreased CoQ 10 levels in skin fibroblasts. Consequently, cultured skin fibroblasts from patients with primary CoQ 10 deficiency have been utilized for biochemical characterization of CoQ 10 biosynthetic defects, in vitro evaluation of pathogenic mechanisms and in vitro assessments of efficacy of CoQ analogs supplementation.
Skin Fibroblasts for Diagnosis of Primary CoQ 10 Deficiency
Once CoQ 10 deficiency is confirmed in patients' muscle and skin fibroblasts, assessment of CoQ 10 biosynthesis in cultured skin fibroblasts can be used to prove the defect in the CoQ 10 biosynthetic pathway. These assays utilize radiolabeled substrates for the biosynthesis of CoQ 10 [López et al., 2006; Quinzii et al., 2006; Mollet et al., 2007; Tekle et al., 2008] [López et al., 2006] . Multiple steps in the CoQ 10 biosynthetic pathway downstream of COQ2 cannot be distinguished with the available assays, but this may become possible in the future by the generation of new radiolabeled intermediates or by using tandem mass spectrometry methods to identify the accumulation of abnormal metabolites [Xie et al., 2012] . In fact, the accumulation of an abnormal metabolite was found in the COQ9 mutant fibroblasts by the routine electrochemical-high-performance liquid chromatography methods [Duncan et al., 2009] . However, identification of the chemical structure of this metabolite is not possible with high-performance liquid chromatography techniques.
Bioenergetics Defects and Oxidative Stress
The disparate phenotypes of CoQ 10 -deficient patients suggest divergent pathogenic mechanisms in this syndrome. To address this issue, research laboratories have studied various molecular and biochemical changes of cultured skin fibroblasts from patients with primary CoQ 10 deficiency. Initially, effects of CoQ 10 deficiency on mitochondrial bioenergetics were assessed because of its essential function for mitochondrial ATP synthesis as an electron carrier from mitochondrial complexes I and II to complex III [Geromel et al., 2001 [Geromel et al., , 2002 Quinzii et al., 2008b . In addition, inherited mitochondrial respiratory chain defects frequently result in increased oxidative stress [Kirkinezos and Moraes, 2001] , and CoQ 10 is recognized as an important endogenous antioxidant, which protects the cell both directly by preventing lipid peroxidation and indirectly by regenerating other antioxidants such as vitamins C and E [Mellors and Tappel, 1966; Turunen et al., 2004] ; therefore, a second focus has been on the consequences of CoQ 10 deficiency on the fibroblasts' oxidative status. Geromel et al. [2001 Geromel et al. [ , 2002 , studying CoQ 10 -deficient fibroblasts of unknown genetic etiology, showed mild defects of mitochondrial respiration and growth rate, but no signs of oxidative stress. López-Martín et al. [2007] also showed defects in the ubiquinone-dependent complexes activities, CI+III and CII+III, in CoQ 10 deficiency fibroblasts with a COQ2 mutation. Quinzii et al. [2008b] demonstrated that CoQ 10 -deficient fibroblasts with PDSS2 mutations and ∼ 20% of residual CoQ 10 showed a severe bioenergetics defect, but no signs of oxidative stress, whereas COQ2 mutant fibroblasts with ∼ 40% of residual CoQ 10 showed less severe bioenergetics defects with striking signs of oxidative stress. Similar to the PDSS2 mutant fibroblasts, COQ9 mutant fibroblasts with ∼ 15% residual CoQ 10 showed bioenergetics defects without oxidative stress, whereas fibroblasts from an additional patient with 165 COQ2 mutations and ∼ 35% residual CoQ 10 manifested increased oxidative stress markers . The study was also extended to fibroblasts from 3 different CoQ 10 -deficient patients due to ADCK3 mutations and >50% of residual CoQ 10 . In these cases, very mild defects in ATP levels were observed, and no signs of oxidative stress were detected. Taken together, the results indicated that the levels of CoQ 10 correlate with reactive oxygen species (ROS) production and oxidative damage: 10-20% and >50% residual CoQ 10 are not associated with significant oxidative stress, whereas 25-45% residual CoQ 10 is accompanied by increased ROS production and oxidative damage ( fig. 1 ). Nevertheless, because the increase of oxidative stress was only limited to COQ2 mutant fibroblasts, it was possible that defective 4-parahydroxybenzoate:polyprenyl transferase (COQ2) protein specifically produced ROS. For this reason, Quinzii et al. [2012] evaluated mitochondrial bioenergetics and oxidative stress in cultured fibroblasts with CoQ 10 deficiency induced by pharmacological inhibition of CoQ 10 biosynthesis. The drug used to inhibit CoQ 10 biosynthesis, 4-nitrobenzoate (4-NB), competes with 4-HB in the reaction catalyzed by COQ2 [Forsman et al., 2010] . Pharmacological inhibition of CoQ 10 biosynthesis led to 55-70% decreases of the endogenous CoQ 10 (30-45% residual CoQ 10 relative to normal) in both control and ADCK3 mutant fibroblasts. As a consequence of this, there were decreases in ATP levels and increases in ROS production and oxidative damage [Quinzii et al., 2012] . These results confirmed that a range of 30-45% of residual CoQ 10 is the key factor in generating ROS ( fig. 1 ) . However, the fundamental mechanisms of ROS generation associated with CoQ 10 deficiency in human skin fibroblasts remain to be elucidated. In this regard, 2 possible mechanisms operating in mitochondria may be responsible: (1) reduction of CoQ-dependent CI+III activity may increase the NADH/NAD+ ratio in the matrix, leading to an increase of O 2 formation through the FMN group of the CI [Murphy, 2009] ; or (2) increased proton motive force (e.g. increased mitochondrial membrane potential) without concomitant enhanced ATP synthesis, leading to increased ROS production [Korshunov et al., 1997; Murphy, 2009 ]. This second possibility is particularly relevant because hyperpolarization of mitochondria and increased ROS production have been observed in fibroblasts with 30-45% of residual CoQ 10 [Quinzii et al., , 2012 . The reason for the increased mitochondrial membrane potential may apply to other respiratory chain defects because the F 1 F 0 -ATPase (complex V) activity is regulated by 2 factors: free energy of the adenosine phosphates and proton electrochemical potential. Thus, in the setting of impaired respiration, membrane potential is initially decreased, but if the cells have sufficient ATP supply, e.g. by the upregulation of glycolysis, complex V may operate as a proton-translocating ATPase, increasing the membrane potential by pumping protons in reverse [Scott and Nicholls, 1980; McKenzie et al., 2007] . Nevertheless, this mechanism does not explain how differences in mitochondrial membrane potential increase ROS generation in fibroblasts with 20-45% residual CoQ 10 .
From a bioenergetics point of view, another interesting observation is the reduced levels of subunits of complex III and IV with normal levels of complex I subunits in immunoblots of extracts of CoQ 10 -deficient fibroblasts with COQ2 mutations or other unknown etiological defects [Rodríguez-Hernández et al., 2009] . The authors suggested that CoQ 10 deficiency may affect the activity, organization and assembly of complex III as it has been reported in yeast [Santos-Ocaña et al., 2002] , with a secondary effect on complex IV. Further experiments are needed to confirm these results in CoQ 10 -deficient fibroblasts with different molecular defects and whether the destabilization of complex III is the cause or the effect of increased ROS production associated with CoQ 10 deficiency. 
Apoptosis, Necrosis and Mitophagy
Increased oxidative stress and ATP depletion have been described as initial events promoting mitochondrial-mediated apoptotic cell death. In studies of CoQ 10 -deficient skin fibroblasts, found that only the COQ2 mutant fibroblasts showed increased apoptotic cell death. Because these cells also showed increased ROS production, the authors hypothesized that the induction of apoptosis was related to increased oxidative stress. Whether the oxidative stress-induced cell death was specific to COQ2 defects or due to the severity of CoQ 10 deficiency was assessed by the pharmacological inhibition of CoQ 10 biosynthesis [Quinzii et al., 2012] . Once again, skin fibroblasts with 30-45% of residual CoQ 10 were associated with cell death as a consequence of the increased oxidative stress and independent of the molecular defect [Quinzii et al., 2012] . Another interesting observation of these studies is that, contrary to the initial expectations, PDSS2 and COQ9 mutant fibroblasts did not show increased cell death, despite the cells' severe depletion of ATP ( fig. 2 ) . One possible explanation is that cells with <20% of residual CoQ 10 acquire resistance to mitochondrial stress-induced apoptosis, compared to those with partial blockage of respiratory chain electron flux associated with a heightened sensitivity to cell death, as has been previously reported [Dey and Moraes, 2000; Park et al., 2004; . In support of this notion, studies have indicated that mitophagy can selectively degrade dysfunctional mitochondria preventing the mitochondrial-dependent apoptotic cell death. In CoQ 10 -deficient fibroblasts, Rodríguez-Hernández et al. [2009] observed increased levels of lysosomal markers and enhanced expression of transcriptional and translational levels of autophagic genes in cell lines carrying COQ2 mutations and in 2 other cell lines from patients with CoQ 10 deficiency and unknown molecular defects. Because inhibition of autophagy resulted in apoptotic cell death, the authors suggested that autophagy is a protective mechanism involved in the degradation of dysfunctional mitochondria ( fig. 2 ) [Rodríguez-Hernández et al., 2009] . Thus, PDSS2 and COQ9 mutant fibroblasts may have increased mitophagy to remove dysfunctional mitochondria. Additionally, compensatory production of ATP via upregulation of glycolysis may also protect cells by decreasing oxidative stress and associated cell death [Quinzii et al., 2008b] .
Pyrimidine Metabolism
In addition to its bioenergetics and antioxidant role, CoQ 10 is also a cofactor in the reaction catalyzed by the mitochondrial protein dihydroorotate dehydrogenase [Rawls et al., 2000] . This enzyme catalyzes the oxidation of dihydroorotate to orotate at the FMN group, which is reduced to FMNH 2 . FMNH 2 is then re-oxidized by reaction with ubiquinone, which is reduced to ubiquinol [Rawls et al., 2000] . The product of the reaction, orotate, is an intermediate of the de novo synthesis of the pyrimidines by the conversion to the ribonucleotide UMP, which can be converted through subsequent reactions in pyrimidine ribonucleotides and deoxyribonucleotides [Löffler et al., 1997; Rawls et al., 2000] . The conversion of ribonucleotides into deoxyribonucleotides is catalyzed by the ribonucleotide reductases [Nordlund and Reichard, 2006] . Until recently, it was thought that mtDNA replication and repair in quiescent cells was dependent on salvage synthesis of deoxynucleotide triphosphates [Ferraro et al., 2005] , but the scenerio changed suddenly with the identification of mutations in a p53 inducible small ribonucleotide reductase subunit, called p53R2 [Tanaka et al., 2000] in patients with mtDNA depletion [Bourdon et al., 2007] . Subsequent experiments confirmed that the de novo supply of deoxynucleotide triphosphates is required for replication and repair of mtDNA in cells and mice [Bourdon et al., 2007; Pontarin et al., 2008] . As a consequence of these findings, it has been postulated that the mtDNA depletion identified in the muscle of a patient with CoQ 10 deficiency may be the result of the reduction in the deoxynucleotide triphosphates supply [Montero et al., 2009] . mtDNA depletion has also been described in skin fibroblasts with COQ2 mutations , and the slow rates of growth observed in these fibroblasts were restored by addition of uridine in the culture medium [López-Martín et al., 2007] ( fig. 2 ) . Alternatively, it is possible that the uridine effect in the growth rate of the COQ2 mutant fibroblasts may be due to the role of uridine metabolism in the gycolysis through the catabolism of galactose [Petry and Reichardt, 1998 ].
Treatment Evaluation in CoQ 10 -Deficient Skin Fibroblasts
The only therapeutic option currently available for CoQ 10 deficiency syndrome is exogenous CoQ 10 supplementation. However, of patients with identified mutations, only 20% improved after exogenous CoQ 10 supplementation [Rahman et al., 2001; López et al., 2006; Diomedi-Camassei et al., 2007; Mollet et al., 2007 Mollet et al., , 2008 Lagier-Tourenne et al., 2008; Montini et al., 2008; Heeringa et al., 2011] . In order to understand the low percentage of successful treatments, studies have evaluated the effects of CoQ 10 supplementation in CoQ 10 -deficient fibroblasts. We attempted to counteract the bioenergetics defect and oxidative stress of the CoQ 10 -deficient fibroblasts by adding 5 μ M of CoQ 10 in culture cells . The results showed that CoQ 10 supplementation for 1 week, but not for 24 h, improved ATP levels and ATP/ADP ratio. Similar to these results, yeast coq mutants showed an inefficient uptake of exogenous CoQ 6 to the mitochondrial inner membrane, which was reflected in a low succinate cytochrome c reductase activity after 2-15 μ M CoQ 6 supplementation for 48 h [Do et al., 2001; Santos-Ocaña et al., 2002] . The complete rescue of growth of the yeast coq mutants supplemented with 15 μ M CoQ 6 was only possible after 6-8 days [Do et al., 2001; Jonassen et al., 2002; Santos-Ocaña et al., 2002] . In contrast to these results, López-Martín et al. [2007] noted normalization of mitochondrial complexes I+III and II+III activities in COQ2 mutant fibroblasts after 24 h of 10 μ M CoQ 10 supplementation. Paradoxically, the same authors, using the same COQ2 mutant cells and other genetically undefined CoQ 10 -deficient fibroblasts, found that the activities of complex II+III increased only slightly and remained below control values after 72 h of 100 μ M CoQ 10 supplementation [Rodríguez-Hernández et al., 2009] . This discrepancy may be due to the fact that in the second study, but not in the first, respiratory chain enzyme activities were normalized to activity of citrate synthase [Rodríguez-Hernández et al., 2009 ], a marker of mitochondrial mass [Kirby et al., 2007] . The discrepant results may be also explained by different methodologies used to evaluate mitochondrial bioenergetics after CoQ 10 supplementation: López et al. [2010] measured cellular ATP levels and ATP/ ADP ratio; in the other 2 studies spectrophotometric methods were used to measure activities of CoQ-dependent complexes. The enzymatic activity assay may produce artifacts due to sonication, freeze-thaw, or detergents that fracture mitochondria and allow access of the CoQ 10 accumulated in the cellular membrane to the inner mitochondrial membrane. Additionally, these manipulations disrupt the mitochondrial supercomplexes, minimizing the differences between the experimental groups [Kruse et al., 2008] . Finally, the different sources of the CoQ 10 , its different formulations and the different solubilization methods may also influence the experimental results.
Because in vitro studies suggested that high lipophilicity of CoQ 10 is the major cause of delayed effects of CoQ 10 supplementation, the effects of less lipophilic ubiquinone analogs with shorter isoprenoid tail were also tested. However, the 2 short-tail ubiquinone analogs, CoQ 2 and idebenone, did not correct bioenergetics defects , which highlights the importance of the decaprenyl tail. Despite the lack of correction of the bioenergetics defect in COQ2 mutant fibroblasts, all of the CoQ analog tested decreased superoxide anion production and oxidative stress-induced cell death . Thus, the in vitro study of CoQ 10 -deficient fibroblasts revealed important insights regarding CoQ 10 supplementation therapy: (1) the prolonged pharmacokinetics of CoQ 10 in restoring respiratory chain activity in CoQ 10 -deficient cells [Bentinger et al., 2003 ], a factor that may contribute to the late clinical response to the oral supplementation of CoQ 10 [Montini et al., 2008] and suggest that high doses of CoQ 10 must be administered; (2) shorttail ubiquinone analogs do not substitute for CoQ 10 in the mitochondrial respiratory chain revealing the importance of the decaprenyl tail; and (3) oxidative stress and cell death can be ameliorated by the administration of lipophilic and hydrophilic antioxidants .
Concluding Remarks
Studies of CoQ 10 -deficient fibroblasts indicate that primary CoQ 10 deficiencies cause variable defects on ATP synthesis, oxidative stress and cell death, which appear to be related to the specific molecular defect, residual level of CoQ 10 , or both ( fig. 2 ) . Therapy leads to the amelioration of these effects. Mitochondrial apoptosis has been observed in CoQ 10 -deficient cells; however, the pathways involved in the induction of this pathway remain to be elucidated. The studies in CoQ 10 -deficient fibroblasts have been limited by the small number of available cell lines. The clinical heterogeneity and tissue-specificity of CoQ 10 deficiency syndrome suggest that differentiated cells may respond to the deficit in ubiquinone differently compared to fibroblasts. In support of this premise, a recent study in a human neuronal model of CoQ 10 deficiency has shown different degrees of mitochondrial respiratory chain dysfunction and oxidative stress relative to CoQ 10 -deficient fibroblasts [Duberly et al., 2013] . Future studies on additional cellular and animal models will help us understand the clinical heterogeneity of CoQ 10 deficiency syndrome and may contribute to the development of more effective therapies.
